Compare Northrop Grumman Corporation (NOC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs ResMed Inc. — how do they compare? Northrop Grumman Corporation trades at $519.79 (market cap $73.24B), while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: Northrop Grumman Corporation is far larger — about 2.3× ResMed Inc.'s market cap, and Northrop Grumman Corporation pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| NOC | RMD | |
|---|---|---|
Market Cap | $73.24B | $31.73B |
Sector | Industrials | Health |
52-Week High | $768.02 | $283.28 |
52-Week Low | $496.02 | $182.82 |
Enterprise Value | $87.23B | $31.08B |
Dividend Yield | 1.92% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with a bullish technical oscillator signal despite bearish moving averages. The company shows strong fundamentals with consistent earnings beats, 10.48% net margin, and record $105 billion backlog. Recent news highlights defense spending growth and successful technology tests, while institutional ownership increased significantly in Q2 2026.
Outlook remains positive with 57% analyst buy ratings and $618.43 consensus target offering 19% upside. Key risks include defense budget volatility and execution challenges on large contracts. Revenue growth acceleration to 10.48% margin by 2026 supports valuation at reasonable 16.37 P/E multiple.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
